Nothing said here yet.
to join the conversation.
— Orphan Drug Designation granted for the treatment of primary immune thrombocytopenia — — Underscores the potential of sovleplenib to address significant unmet medical needs in patients with this rare and serious autoimmune condition — — Eligible for…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct.
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting — — Robust PFS gains alongside very encouraging OS clinical benefit in…
— ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO® — — ORPATHYS® plus TAGRISSO® extended median OS by nearly 5 months — —…
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., Oct.
HUTCHMED (China) has delivered mixed results for shareholders, with short term gains set against much weaker longer term returns.
AstraZeneca, in collaboration with HUTCHMED, has submitted a New Drug Application to the US FDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) in previously treated EGFR-mutated NSCLC patients with MET overexpression or amplification, supported by…
— Filing seeks approval for a biomarker-directed, all-oral treatment option for patients whose tumors have MET overexpression or amplification, after progression on an EGFR-TKI therapy — — Application supported by SAFFRON, the first global Phase III trial to…
First-in-class KRAS-payload leveraging synchronized EGFR inhibitionHONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept.
On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept.
HUTCHMED (NASDAQ:HCM) said it has entered a co-development and licensing agreement with GSK for ex-China rights to HMPL-A830, a preclinical KRAS-EGFR antibody-targeted therapy conjugate, or ATTC.